AU2001288369A1 - Method of monitoring the effect of cathepsin s inhibitors - Google Patents

Method of monitoring the effect of cathepsin s inhibitors

Info

Publication number
AU2001288369A1
AU2001288369A1 AU2001288369A AU8836901A AU2001288369A1 AU 2001288369 A1 AU2001288369 A1 AU 2001288369A1 AU 2001288369 A AU2001288369 A AU 2001288369A AU 8836901 A AU8836901 A AU 8836901A AU 2001288369 A1 AU2001288369 A1 AU 2001288369A1
Authority
AU
Australia
Prior art keywords
cathepsin
inhibitors
monitoring
effect
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001288369A
Other languages
English (en)
Inventor
Lars Karlsson
Siquan Sun
Robin Thurmond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of AU2001288369A1 publication Critical patent/AU2001288369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466Cysteine endopeptidases (3.4.22)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/962Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/811Test for named disease, body condition or organ function
    • Y10S436/813Cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/825Pretreatment for removal of interfering factors from sample
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125Digestion or removing interfering materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
AU2001288369A 2000-09-06 2001-08-24 Method of monitoring the effect of cathepsin s inhibitors Abandoned AU2001288369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23048400P 2000-09-06 2000-09-06
US60230484 2000-09-06
PCT/US2001/026373 WO2002021129A1 (en) 2000-09-06 2001-08-24 Method of monitoring the effect of cathepsin s inhibitors

Publications (1)

Publication Number Publication Date
AU2001288369A1 true AU2001288369A1 (en) 2002-03-22

Family

ID=22865403

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001288369A Abandoned AU2001288369A1 (en) 2000-09-06 2001-08-24 Method of monitoring the effect of cathepsin s inhibitors

Country Status (10)

Country Link
US (1) US7026132B2 (es)
EP (1) EP1315966B1 (es)
JP (1) JP2004508553A (es)
AT (1) ATE374945T1 (es)
AU (1) AU2001288369A1 (es)
CA (1) CA2421558A1 (es)
DE (1) DE60130784T2 (es)
DK (1) DK1315966T3 (es)
ES (1) ES2295206T3 (es)
WO (1) WO2002021129A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780985B2 (en) 2001-11-08 2004-08-24 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of Canine Cathepsin S
US6784288B2 (en) 2001-11-08 2004-08-31 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of monkey cathepsin S
WO2006125105A2 (en) * 2005-05-19 2006-11-23 Wyeth Methods and compositions for treating and diagnosing multiple sclerosis
EP2436776A1 (en) 2010-10-01 2012-04-04 F. Hoffmann-La Roche AG Method for monitoring Cathepsin S inhibition
WO2016041915A1 (en) 2014-09-18 2016-03-24 F. Hoffmann-La Roche Ag Method for monitoring cathepsin s inhibition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US6245904B1 (en) * 1995-09-14 2001-06-12 The University Of Tubingen Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific T-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide
CA2251714A1 (en) * 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
WO1997049430A1 (en) * 1996-06-26 1997-12-31 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
WO1999058153A1 (en) * 1998-05-08 1999-11-18 Brigham & Women's Hospital Methods of diagnosing and modulating autoimmunity
US6495333B1 (en) * 1998-09-22 2002-12-17 Becton Dickinson And Company Flow cytometric, whole blood dendritic cell immune function assay

Also Published As

Publication number Publication date
DE60130784T2 (de) 2008-07-17
DE60130784D1 (de) 2007-11-15
JP2004508553A (ja) 2004-03-18
ATE374945T1 (de) 2007-10-15
DK1315966T3 (da) 2008-01-02
ES2295206T3 (es) 2008-04-16
US7026132B2 (en) 2006-04-11
EP1315966B1 (en) 2007-10-03
US20020028435A1 (en) 2002-03-07
EP1315966A4 (en) 2005-07-27
EP1315966A1 (en) 2003-06-04
WO2002021129A1 (en) 2002-03-14
CA2421558A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
GB2367594B (en) Calibration of pumps, such as blood pumps of dialysis machines
AU2002309757A1 (en) Process and system for prescribing, administering and monitoring a treatment regimen for a patent
PT1258476E (pt) Derivados de alfa-amino-acidos, processo para sua preparacao assim como a sua utilizacao como inibidores de dipeptidil-peptidase iv (dpp iv).
DE60208448D1 (de) Manschette für Blutdrucküberwachung
EA200000814A1 (ru) Фармацевтическая композиция топирамата
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
AU2002352531A1 (en) Use of at least one glycoinhibitor substance
WO2000038666A3 (en) A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
ITMI20031343A1 (it) Confezione plurima, e macchina e metodo per la sua fabbricazione.
AU2001288369A1 (en) Method of monitoring the effect of cathepsin s inhibitors
AU2001247863A1 (en) Method for systolic blood pressure measurement
WO2002083713A3 (en) Echinocandin process
ATE515266T1 (de) 2-(amino-3,4-dioxo-1-cyclobuten-1- yl)aminoalkylsäure-derivate für die schmerzbehandlung
WO2002066068A3 (en) Method of treating neurological diseases
MXPA02002644A (es) Metodo de diagnostico mejorado para detectar tejido de epitelio displastico.
EP1591130A3 (en) Use of active solution for disinfecting and/or sterilizing a dental unit and method thereof
MY141756A (en) Use of phenoxyacetic acid derivatives for treating hyperactive bladder
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
AU2001292669A1 (en) Blood pressure measuring apparatus
IL156639A0 (en) Phenethanolamine derivatives, methods for their preparation and pharmaceutical compositions containing them
SE0202608D0 (sv) New sequences
WO2002036069A3 (en) Hypotension